Protective effects of the combination of α-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 6, 2008, Pages 1332-1338

  Cirioni, Oscar ^a   Silvestri, Carmela ^a   Ghiselli, Roberto ^a   Orlando, Fiorenza ^b   Riva, Alessandra ^a   Mocchegiani, Federico ^a   Chiodi, Leonardo ^a   Castelletti, Sefora ^a   Gabrielli, Eleonora ^a   Saba, Vittorio ^a   Scalise, Giorgio ^a   Giacometti, Andrea ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INRCA   (Italy)

Author keywords

Animal model; Multiresistant organisms; P. aeruginosa; Sepsis; Synergy

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CECROPIN A; ENDOTOXIN; MAGAININ 2; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; GRAM NEGATIVE INFECTION; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN BLOOD LEVEL; PSEUDOMONAS AERUGINOSA;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BLOOD; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENDOTOXINS; INJECTIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PERITONEUM; PIPERACILLIN; PLASMA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RATS; RATS, WISTAR; RIFAMPIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; XENOPUS PROTEINS;

EID: 56649116095     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn393     Document Type: Article

References (31)

1. Sakr Y, Vincent JL, Schuerholz T et al. Early- versus late-onset shock in European intensive care units. Shock 2007; 28: 636-43.
2. Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43 Suppl 2: S43-8.
3. Torres JA, Villegas MV, Quinn JP. Current concepts in antibiotic-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther 2007; 5: 833-43.
4. Landman D, Bratu S, Alam M et al. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J Antimicrob Chemother 2005; 55: 954-7.
5. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am J Infect Control 2006; 34: S3-10.
6. Carmeli Y, Troillet N, Eliopoulos GM et al. Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43: 1379-82.
7. Cannon M. A family of wound healers. Nature 1987; 328: 478.
8. Boman HG. Antibacterial peptides: Basic facts and emerging concepts. J Intern Med 2003; 254: 197-215.
9. Ghiselli R, Cirioni O, Giacometti A et al. The cathelicidin-derived tritrpticin enhances the efficacy of ertapenem in experimental rat models of septic shock. Shock 2006; 26: 195-200.
10. Giacometti A, Cirioni O, Barchiesi F et al. Antimicrobial activity of polycationic peptides. Peptides 1999; 20: 1265-73.
11. Scott MG, Yan H, Hancock REW. Biological properties of structurally related a-helical cationic antimicrobial peptides. Infect Immun 1999; 67: 2005-9.
12. Wade D, Boman A, Wâhlin B et al. All-D amino acid-containing channel-forming antibiotic peptides. Proc Natl Acad Sci USA 1990; 87: 4761-5.
13. Hultmark D, Steiner H, Rasmuson T et al. Insect immunity. Purification and properties of three inducible bactericidal proteins from hemolymph of immunized pupae of Hyalophora cecropia. Eur J Biochem 1980; 106: 7-16.
14. Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: Isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci USA 1987; 84 5449-53.
15. Steffee CH, Morrell RM, Wasilauskas BL. Clinical use of rifampin during routine reporting of rifampin susceptibilities: A lesson in selective reporting of antimicrobial susceptibility data. J Antimicrob Chemother 1997; 40: 595-8.
16. Cirioni O, Ghiselli R, Orlando F et al. Efficacy of colistin/ rifampin combination in experimental rat models of sepsis due to multiresistant P seudomonas aeruginosa strain. Crit Care Med 2007; 35: 1717-23.
17. Cirioni O, Giacometti A, Ghiselli R et al. Citropin 1.1-treated central venous catheters improve the efficacy of hydrophobic antibiotics in the treatment of experimental staphylococcal catheter-related infection. Peptides 2006; 27: 1210-6.
18. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard M7-A6. NCCLS, Villanova, PA, USA, 2003.
19. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
20. Schuldiner S. Structural biology: The ins and outs of drug transport. Nature 2006; 443: 156-7.
21. Vaara M. Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in Gram-negative enteric bacteria. Antimicrob Agents Chemother 1993; 37: 354-6.
22. Livermore D. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare? Clin Infect Dis 2002; 34: 634-40.
23. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: Old antibiotics for emerging multiresistant Gram-negative bacteria. Ann Pharmacother 1999; 33: 960-7.
24. Vaara M, Porro M. Group of peptides that act synergistically with hydrophobic antibiotics against Gram-negative enteric bacteria. Antimicrob Agents Chemother 1996; 40: 1801-5.
25. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 2003; 55: 27-55.
26. Iwagaki A, Porro M, Pollack M. Influence of synthetic antiendotoxin peptides on lipopolysaccharide (LPS) recognition and LPS-induced proinflammatory cytokine responses by cells expressing membrane-bound CD14. Infect Immun 2000; 68: 1655-63.
27. Yethon JA, Whitfield C. Lipopolysaccharide as a target for the development of novel therapeutics in Gram-negative bacteria. Curr Drug Targets Infect Disord 2001; 1: 91-106.
28. Hirsch T, Metzig M, Niederbichler A et al. Role of host defense peptides of the innate immune response in sepsis. Shock 2008; 30: 117-26.
29. Ziglam HM, Daniels I, Finch RG. Immunomodulating activity of rifampin. J Chemother 2004; 16: 357-61.
30. Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2001; 40: 117-20.
31. Balakrishna R, Wood SJ, Nguyen TB et al. Structural correlates of antibacterial and membrane-permeabilizing activities in acylpolyamines. Antimicrob Agents Chemother 2006; 50: 852-61.